Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.37 |
| ▸ | BRAF | P15056 | 9/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.36 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.36 |
| ▸ | RAF1 | P04049 | 2/20 | 0.35 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5056399 | 0.92 | MAPK14 (0.44) | KDRBRAFMAPK14LCK | |
| SCHEMBL5055043 | 0.91 | MAPK14 (0.46) | KDRBRAFMAPK14 | |
| SCHEMBL5052398 | 0.90 | KDR (0.39) | KDRBRAFMAPK14TNNI3KRAF1 | |
| SCHEMBL5052213 | 0.90 | KDR (0.37) | KDRBRAFMAPK14RIPK2 | |
| SCHEMBL5056291 | 0.85 | KDR (0.38) | KDRBRAFMAPK14TNNI3KRAF1 | |
| SCHEMBL5055062 | 0.85 | NPC1 (0.39) | KDRBRAFMAPK14TNNI3KRAF1 | |
| SCHEMBL5062305 | 0.85 | KDR (0.43) | KDR | |
| SCHEMBL5055064 | 0.84 | ABL1 (0.46) | KDRBRAFMAPK14TNNI3KRAF1 | |
| SCHEMBL5055284 | 0.84 | MAPK14 (0.55) | KDRBRAFMAPK14 | |
| SCHEMBL5055058 | 0.83 | IMPDH2 (0.40) | KDRBRAFMAPK14TNNI3KRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | KDR 41/4885BRAF 2/4885MAPK14 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.